Outcome of prenatally diagnosed isolated congenital complete atrioventricular block treated with transplacental betamethasone or ritodrine therapy.
The effectiveness of transplacental drug therapy for prenatally diagnosed isolated congenital complete atrioventricular block (CCAVB) is controversial. Nine cases of prenatal isolated CCAVB were treated from 2002 to 2007. Ritodrine was administered transplacentally to all fetuses and betamethasone to those whose mothers tested positive for maternal anti-SSA/Ro antibodies. Six of the nine patients had an anti-SSA/Ro-positive mother and received transplacental betamethasone 4 mg/day at a median gestational age of 28 weeks (range, 24-31 weeks). No patients exhibited an improvement in the degrees of complete heart block, and one patient died in utero. No serious adverse events occurred. After the mean follow-up period of 1.7 +/- 1.3 years, all five patients treated with transplacental betamethasone experienced a good cardiac function, whereas one of the three patients not treated with transplacental betamethasone experienced cardiomyopathy and died at the age of 4 months. Pacemaker implantation was required for seven of the eight live-born infants. Transplacental betamethasone therapy for the patients with isolated CCAVB neither improved the degree of atrioventricular block nor decreased the rate of patients requiring pacemaker implantation, but it probably reduced the risk for the development of myocardial disease.
Hayashi
Taiyu
T
Division of Pediatric Cardiology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan. hayashi-t@ncchd.go.jp
Kaneko
Masahide
M
Kim
Ki-Sung
KS
Eryu
Yoshihiko
Y
Shindo
Takahiro
T
Isoda
Takayoshi
T
Murashima
Atsuko
A
Ito
Yushi
Y
Sago
Haruhiko
H
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D054537:Atrioventricular Block / Q000151:congenital / Q000175:diagnosis / Q000188:drug therapy*; D001623:Betamethasone / Q000627:therapeutic use*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D015160:Hydrops Fetalis; D007231:Infant, Newborn; D008297:Male; D010920:Placenta; D011247:Pregnancy; D011256:Pregnancy Outcome; D011296:Prenatal Diagnosis; D011446:Prospective Studies; D012312:Ritodrine / Q000627:therapeutic use*; D016896:Treatment Outcome
D000318:Adrenergic beta-Agonists; D005938:Glucocorticoids; D001623:Betamethasone; D012312:Ritodrine